Suppr超能文献

比较卒中团队与直升机紧急医疗服务提供者之间的国立卫生研究院卒中量表。

Comparing National Institutes of Health Stroke Scale among a stroke team and helicopter emergency medical service providers.

作者信息

Kesinger Matthew R, Sequeira Denisse J, Buffalini Samantha, Guyette Francis X

机构信息

From the University of Pittsburgh, PA (M.R.K., D.J.S., F.X.G.); and Duquesne University, Pittsburgh, PA (S.B.).

出版信息

Stroke. 2015 Feb;46(2):575-8. doi: 10.1161/STROKEAHA.114.007850. Epub 2014 Dec 23.

Abstract

BACKGROUND AND PURPOSE

The use of tissue-type plasminogen activator is limited to a maximum of 4.5 hours after symptom-onset. Endovascular recanalization may improve outcomes for large-vessel occlusions (LVO), but efficacy decreases with time from symptom-onset. A National Institutes of Health Stroke Scale (NIHSS) score ≥12 is predictive of LVOs and could be used to triage patients if appropriately used by prehospital providers. The NIHSS has been considered too complex and has not been validated in the prehospital setting.

METHODS

We reviewed all patients with ischemic stroke transported by helicopter emergency medical services (HEMS) to a single comprehensive stroke center in 2010. HEMS NIHSS were compared with in-hospital stroke team physician scores. NIHSS was categorized based on 3 clinically relevant groupings and ability to predict LVO was investigated.

RESULTS

Three-hundred five patients met inclusion criteria, 68.9% having LVO. Moderate agreement existed between HEMS and physicians (72.1%; κ=0.571). Interclass correlation was 0.879 (95% confidence interval, 0.849-0.904). Excluding patients with tissue-type plasminogen activator before HEMS transport, there were 216 patients and good agreement (82.7%; κ=0.619). Among patients presenting within 8 hours postonset and NIHSS≥12, HEMS had a sensitivity of 55.9% and positive predictive value of 83.7% in predicting LVO.

CONCLUSIONS

HEMS providers can administer NIHSS with moderate to good agreement with the receiving stroke team. The use of the NIHSS in HEMS may identify patients with LVO and inform triage decisions for patients ineligible for tissue-type plasminogen activator.

摘要

背景与目的

组织型纤溶酶原激活剂的使用仅限于症状发作后最多4.5小时。血管内再通可能改善大血管闭塞(LVO)患者的预后,但疗效会随着症状发作时间的延长而降低。美国国立卫生研究院卒中量表(NIHSS)评分≥12可预测LVO,若能被院前急救人员合理使用,可用于对患者进行分类。NIHSS被认为过于复杂,且尚未在院前环境中得到验证。

方法

我们回顾了2010年通过直升机紧急医疗服务(HEMS)转运至单一综合卒中中心的所有缺血性卒中患者。将HEMS的NIHSS评分与院内卒中团队医生的评分进行比较。根据3种临床相关分组对NIHSS进行分类,并研究其预测LVO的能力。

结果

305例患者符合纳入标准,其中68.9%患有LVO。HEMS与医生之间存在中度一致性(72.1%;κ=0.571)。组内相关系数为0.879(95%置信区间,0.849 - 0.904)。排除在HEMS转运前接受组织型纤溶酶原激活剂治疗的患者后,有216例患者,一致性良好(82.7%;κ=0.619)。在症状发作后8小时内就诊且NIHSS≥12的患者中,HEMS预测LVO的敏感性为55.9%,阳性预测值为83.7%。

结论

HEMS急救人员使用NIHSS的结果与接收卒中团队的结果具有中度至良好的一致性。在HEMS中使用NIHSS可能识别出患有LVO的患者,并为不符合组织型纤溶酶原激活剂治疗条件的患者提供分类决策依据。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验